BSESharpline Broadcast Ltd· MediaHighNeutral
Announced Tue, 18 Nov, 2025 · 18:33 IST

We are hereby submitting the financial results under regulation 33 of SEBI (LODR) Regulation, 2015, board of director considered and approved in board meeting held on 14th November and ....

Revenue Growth 20pctPat NegativeEbitda Margin CompressionNegative Operating CashflowDebt Equity ThresholdResults View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+1.7%Reaction day
₹11.88
prior close
₹11.88
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.2%+1.9% vs market
Advertising & Media Agencies peers, median of 8sector+0.2%+1.5% vs sector

On the reaction day the stock moved 1.9 pts more than Nifty Microcap 250 and 1.5 pts more than its Advertising & Media Agencies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+1.0
10m
+1.0
15m
+5.1
30m
+3.0
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+1.7-0.2+1.9+0.2+1.5
Next day
-6.4-0.5-5.9+0.8-7.2
2d
-7.4-2.0-5.4-1.8-5.6
3d
-7.3-2.6-4.7-4.2-3.1
4d
-11.7-2.5-9.2-3.9-7.8
5d
-13.7-1.2-12.5-0.9-12.8
1w
+3.4-1.7+5.1-2.7+6.1
15d
-14.1-5.6-8.6-6.0-8.1
1m
-11.6-5.0-6.6-5.2-6.4
2m
-8.1-9.0+1.0-11.3+3.2
3m
-7.4-7.7+0.3-16.6+9.1
UpDownMarket · Nifty Microcap 250Sector · Advertising & Media Agencies peers, median of 8Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sharpline Broadcast's board meeting, originally scheduled for November 14, was adjourned multiple times due to financial observations raised by statutory auditors and delays in receiving required financial statements, finally concluding on November 18, 2025. On a standalone basis, H1 FY26 revenue grew about 41% year-on-year to ₹2,166.24 lakhs, but the company slipped deeper into losses with a net loss of ₹487.10 lakhs versus ₹456.41 lakhs in H1 FY25. On a consolidated basis, revenue jumped sharply to ₹5,048.81 lakhs (up from ₹1,531.56 lakhs), largely driven by a new Medicine segment, yet the group reported a loss of ₹443.64 lakhs. Operating cashflow turned sharply negative at around negative ₹1,193 lakhs compared to a positive ₹223.66 lakhs a year ago. Total consolidated borrowings rose to about ₹2,607 lakhs against equity of ₹2,384 lakhs, pushing the debt-to-equity ratio above 1. The statutory auditor (BAS & Co. LLP) issued an unqualified limited review report.

Likely market impact

Despite strong top-line growth, widening losses, negative operating cashflows, rising debt, and the unusual delay in finalising results with auditor concerns are significant red flags for shareholders. The stock could face negative sentiment and volatility when trading resumes on November 21, 2025.